411 related articles for article (PubMed ID: 12204057)
1. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
2. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Korshunov AG; Shishkina LV; Golanov AV
Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome.
Korshunov A; Shishkina L; Golanov A
Int J Cancer; 2003 May; 104(6):728-34. PubMed ID: 12640680
[TBL] [Abstract][Full Text] [Related]
4. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas.
Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P
Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical evaluation of intracranial recurrent meningiomas: correlation of topoisomerase II alpha expression and cell proliferative potential].
Tanaka M; Kubo O; Tajika Y; Takahashi T; Suzuki S; Takakura K
No To Shinkei; 1999 Dec; 51(12):1033-9. PubMed ID: 10654298
[TBL] [Abstract][Full Text] [Related]
6. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
7. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Korshunov A; Golanov A
Arch Pathol Lab Med; 2001 Jul; 125(7):892-8. PubMed ID: 11419973
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
Winther TL; Torp SH
PLoS One; 2017; 12(3):e0172316. PubMed ID: 28301542
[TBL] [Abstract][Full Text] [Related]
11. Value of KI-67/MIB-1 labeling index and simpson grading system to predict the recurrence of who grade I intracranial meningiomas compared to who grade II.
Prat-Acín R; Guarín-Corredor MJ; Galeano-Senabre I; Ayuso-Sacido A; Vera-Sempere F
J Clin Neurosci; 2021 Apr; 86():32-37. PubMed ID: 33775343
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II alpha as a reliable proliferation marker in meningiomas.
Roessler K; Gatterbauer B; Kitz K
Neurol Res; 2002 Apr; 24(3):241-3. PubMed ID: 11958416
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
Bruna J; Brell M; Ferrer I; Gimenez-Bonafe P; Tortosa A
Neuropathology; 2007 Apr; 27(2):114-20. PubMed ID: 17494511
[TBL] [Abstract][Full Text] [Related]
14. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Ki-67 Labeling Index and Postoperative Radiotherapy in WHO Grade II Meningioma.
Choi Y; Lim DH; Yu JI; Jo K; Nam DH; Seol HJ; Lee JI; Kong DS; Suh YL; Nam H
Am J Clin Oncol; 2018 Jan; 41(1):18-23. PubMed ID: 26270441
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 immunoreactivity in meningiomas.
Milenković S; Marinkovic T; Jovanovic MB; Djuricic S; Berisavac II; Berisavac I
Cell Mol Neurobiol; 2008 Sep; 28(6):907-13. PubMed ID: 18379871
[TBL] [Abstract][Full Text] [Related]
17. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.
Takeuchi H; Kubota T; Kabuto M; Kitai R; Nozaki J; Yamashita J
Surg Neurol; 1997 Nov; 48(5):501-6. PubMed ID: 9352816
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
Park SH; Suh YL
Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
[TBL] [Abstract][Full Text] [Related]
19. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
20. The significance of nucleolar organizer region (AgNOR) score in predicting meningioma recurrence.
Kunishio K; Ohmoto T; Matsuhisa T; Maeshiro T; Furuta T; Matsumoto K
Cancer; 1994 Apr; 73(8):2200-5. PubMed ID: 8156526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
